Diphosphorus pentaoxide in organic synthesis, XXVII. A one-step synthesis of thiazolo[5,4-d]pyrimidin-7-amines and purine-6-thiones from 5-(acylamino)-2-methyl-4-thiazolecarboxamides
作者:Knud Erik Andersen、Mahmoud Hammad、Erik B. Pedersen
DOI:10.1002/jlac.198619860711
日期:1986.7.14
5-(Acylamino)-2-methyl-4-thiazolecarboxamides 1 have been converted into a series of N-arylthiazolo[5,4-d]pyrimidin-7-amines 2 and 9-aryl-1,9-dihydro-6H-purine-6-thiones 3 by heating in a mixture of diphosphoruspentaoxide, triethylamine hydrochloride, and an appropriate substituted aniline at 240°C for 2 min and then at 160°C for 1 h. The ratio of 2 and 3 depends on the aniline and thiazole used.
5-(酰基氨基)-2-甲基-4-噻唑羧酰胺1已转化为一系列N-芳基噻唑并[5,4- d ]嘧啶7-胺2和9-芳基-1,9-二氢-6 H通过在五氧化二磷,三乙胺盐酸盐和适当的取代苯胺的混合物中于240°C加热2分钟,然后在160°C加热1小时,生成-嘌呤6-硫酮3。2和3的比例取决于所用的苯胺和噻唑。
Thiazolopyrimidine Derivative
申请人:Sugihara Yoshihiro
公开号:US20080269238A1
公开(公告)日:2008-10-30
The present invention provides a compound represented by the following Formula:
wherein A is an aryl group or a heteroaryl group, each of which may be substituted; R
1
is a group which is bonded through carbon; R
2
is hydrogen or an aliphatic hydrocarbon group; and X is —NR
3
—, —O—, —S—, —SO—, —SO
2
—, or —CHR
3
— (wherein R
3
is hydrogen or an aliphatic hydrocarbon group), or a salt thereof, or a prodrug thereof, which has growth factor receptor tyrosine kinase inhibitory activity and low toxicity, and is useful for prevention and treatment of cancer, and thus can be sufficiently used as a medicine.
The present invention provides a compound represented by the following Formula:
wherein A is an aryl group or a heteroaryl group, each of which may be substituted; R1 is a group which is bonded through carbon; R2 is hydrogen or an aliphatic hydrocarbon group; and X is -NR3-, -O-, -S-, -SO-, -SO2-, or -CHR3-(wherein R3 is hydrogen or an aliphatic hydrocarbon group), or a salt thereof, or a prodrug thereof, which has growth factor receptor tyrosine kinase inhibitory activity and low toxicity, and is useful for prevention and treatment of cancer, and thus can be sufficiently used as a medicine.
本发明提供了由下式表示的化合物:
其中 A 是芳基或杂芳基,每个芳基或杂芳基均可被取代;R1 是通过碳键合的基团;R2 是氢或脂肪族烃基;X为-NR3-、-O-、-S-、-SO-、-SO2-或-CHR3-(其中R3为氢或脂族烃基),或其盐,或其原药,具有生长因子受体酪氨酸激酶抑制活性和低毒性,可用于预防和治疗癌症,因此可充分用作药物。
ANDERSEN K. E.; HAMMAD M.; PEDERSEN E. B., LIEBIGS ANN. CHEM.,(1986) N 7, 1255-1261